12 Sep Meta-analysis concludes benefits for CoQ10
Meta-analysis concludes benefits for CoQ10 in chronic kidney disease
December 28, 2018. A review and meta-analysis appearing November 11, 2018 in Current Pharmaceutical Design foundseveral metabolic benefits for supplementation with the antioxidant coenzyme Q10 (CoQ10) by individuals with chronic kidney disease.
“Chronic kidney disease (CKD) is associated with an increased prevalence of all-cause mortality, diabetic nephropathy, cardiovascular events and hospitalization, regardless of existing risk factors and a history of Cardiovascular Disease,” write authors Marzieh Bakhshayeshkaram and colleagues in their introduction. “Increased biomarkers of oxidative stress in these patients has been identified as a major contributor to the pathogenesis of atherosclerosis and other cardiovascular disease in this population.”
Researchers at Shiraz University of Medical Sciences selected seven randomized, controlled trials that included a total of 384 men and women with chronic kidney disease for the meta-analysis. Metabolic profiles evaluated during the trials included measurements of triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, glucose, insulin, insulin resistance, C-reactive protein, malondialdehyde (a marker of oxidative stress) and creatinine (which is elevated in kidney disease). The dosage of CoQ10 in the trials ranged from 30 milligrams (mg) to 200 mg administered for periods of 4 to 12 weeks.
Pooled analysis of the trials’ subjects determined that CoQ10 supplementation was associated with a decrease in total cholesterol, LDL-cholesterol, malondialdehyde and creatinine.
“To our best knowledge, this is the first meta-analysis of RCTs determines the effect of CoQ10 supplementation on metabolic profiles of patients diagnosed with CKD,” the authors announced “Additional prospective studies are necessary to confirm the effects of CoQ10 supplementation on other metabolic profiles in these patients.”